API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationorm PLUS.
Lead Product(s): Fluorometholone Acetate
Therapeutic Area: Ophthalmology Product Name: Flarex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harrow
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 24, 2023
Details:
Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationorm PLUS.
Lead Product(s): Fluorometholone Acetate
Therapeutic Area: Ophthalmology Product Name: Flarex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harrow
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 17, 2023